摘要
目的:探讨帕利哌酮缓释片与齐拉西酮胶囊治疗精神分裂症的疗效、不良反应及对社会功能的影响。方法:选取2013年1月-2014年1月在本院住院的76例精神分裂症患者,按照随机数字表法将其分为对照组和研究组各38例,对照组给予齐拉西酮胶囊口服,研究组给予帕利哌酮缓释片口服,在治疗前、2周末、4周末、8周末给予PANSS量表评定。在治疗前、治疗8周末给予PSP量表评定。不良反应情况给予TESS量表评定。结果:两组PANSS评分在治疗2周末开始下降,比较差异有统计学意义(P<0.05),而两组在治疗前、治疗4周末、治疗8周末比较差异均无统计学意义(P>0.05)。两组在治疗前的PSP量表评分比较差异无统计学意义(P>0.05),而在治疗8周末比较差异有统计学意义(P<0.05)。结论:帕利哌酮缓释片和齐拉西酮胶囊治疗精神分裂症疗效、安全性相当,帕利哌酮缓释片起效较快,在社会功能恢复方面帕利哌酮缓释片优于齐拉西酮胶囊。
Objective： To explore the efficacy and the influence of social function of paliperidone extendedrelease tablets and ziprasidone capsule in the treatment of schizophrenia.Method： Seventy-six patients with schizophrenia in our hospital from January 2013 to January 2014 were selected, they were randomly divided into the control group and the research group, 38 eases in each group.The control group was given orally ziprasidone capsule and the research group was given paliperidone extended-release tablets.The Positive and Negative Syndrome Scale （ PANSS ） at baseline and at the end of 2nd, 4th and 8th week and the Personal and Social performance Scale （ PSP ） at baseline and at zhe end of 8th week were assessed.Adverse reaction conditions was assessed with TESS scale.Result： Two groups of PANSS score in the treatment of 2 weekend began to decline, there were statistically significant differences （P〈0.05） .But there was no statistically significant differences before treatment and after 4 weeks, 8 weeks of treatment （ P〉0.05 ） .PSP score of the two groups before treatment was no statistically significant difference （ P〉0.05 ）, but there was statistically significant differences after 8 weeks treatment （P〈0.05） .Conclusion： Paliperidone extended-release tablets and ziprasidone in the treatment of schizophrenia are similarity, palipefidone extended-release tablets work faster.In terms of social function recovery, paliperidone extended-release tablet is better than that of ziprasidone capsule.
出处
《中国医学创新》
CAS
2014年第20期38-41,共4页
Medical Innovation of China
